Worldwide, blood pressure is the predominant risk factor without threshold above which the event rate suddenly rises. Ambulatory blood pressure (ABP) monitoring substantially refines the risk stratification in patients with hypertension 11 or end-stage renal disease, 12 and in population samples. [13] [14] [15] [16] To our knowledge, no previous study addressed whether in the general population the estimated GFR (eGFR) from the serum creatinine concentration adds to the prediction of cardiovascular outcome over and beyond the 24-hour ambulatory blood pressure (ABP 24 ). We addressed this question in 5322 participants randomly recruited from 11 populations and enrolled in the International Database on Ambulatory blood pressure in relation to Cardiovascular Outcomes (IDACO).
Methods

Study Population
At the time of writing this report, the IDACO 17 included 11 randomly recruited population cohorts and 11 785 participants with available data on the conventional and ABP. We excluded 2361 participants, because they were younger than 18 years (n=252), because their conventional blood pressure was not on the database (n=219), or because they had <10 daytime or 5 nighttime blood pressure readings (n=1890). We additionally disregarded 4017 subjects because serum creatinine had not been measured at enrollment and 85 subjects because their serum creatinine concentration was >3 SDs higher than the center-and sex-specific group mean. Thus, the total number of subjects included in the present analysis totaled 5322 (for details, see the expanded Methods in the online-only Data Supplement).
Blood Pressure Measurement
Methods used for conventional and ABP measurement are described in detail in the expanded Methods (online-only Data Supplement). Hypertension was a conventional blood pressure of ≥140 mm Hg systolic or 90 mm Hg diastolic or the use of antihypertensive drugs. Because of the prognostic superiority of ABP over conventional blood pressure, we based our analysis on the former. 15 We focused on systolic blood pressure, because in middle-aged and older adults this is the predominant risk factor, both on conventional 18 and ambulatory measurement. 16 
Assessment of Renal Function
To measure the serum creatinine concentration, all laboratories applied Jaffe's method 19 with modifications described elsewhere 20, 21 to overcome interferences and limitations. The samples were run on automated analyzers in certified laboratories that participated in external quality control programs. We used the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) 22 to estimate the GFR from sex, age, and the serum creatinine concentration. In a subsample of 2962 participants (55.7%), we checked the presence of proteinuria by means of a semiquantitative dipstick method (n=1287) [23] [24] [25] [26] or by measurement of albumin in a 24-hour urine collection (n=1675). 23, 27 Proteinuria was a positive dipstick test (any degree) or a 24-hour urinary albumin excretion of ≥30 mg. 28 
Other Measurements
We used the questionnaires originally administered in each cohort to obtain information on each participant's medical history and smoking and drinking habits. Body mass index was body weight in kilograms divided by height in meters squared. We measured serum cholesterol and blood glucose by automated enzymatic methods. Diabetes mellitus was the use of antidiabetic drugs, a fasting blood glucose concentration of ≥7.0 mmol/L, 14, [23] [24] [25] [26] 29 a random blood glucose concentration of ≥11.1 mmol/L, 23, 26, 30 a self-reported diagnosis, 23, 30 or diabetes mellitus documented in practice or hospital records.
Ascertainment of Events
We ascertained vital status and the incidence of fatal and nonfatal diseases from the appropriate sources in each country, as described in previous publications. [31] [32] [33] Fatal and nonfatal stroke did not include transient ischemic attacks. Coronary events encompassed death from ischemic heart disease, sudden death, nonfatal myocardial infarction, and coronary revascularization. Cardiac events comprised coronary end points and fatal and nonfatal heart failure. The composite cardiovascular end point included all aforementioned end points plus cardiovascular mortality. In all outcome analyses, we only considered the first event within each category.
Statistical Analysis
For database management and statistical analysis, we used SAS software, version 9.1.3 (SAS Institute, Cary, NC). For comparison of means and proportions, we applied the large sample z test and the χ 2 statistic, respectively. In exploratory analyses, we plotted incidence rates by center-and sex-specific quartiles of the distributions of the 24-hour systolic blood pressure and eGFR, while standardizing by the direct method for center, sex, and age (≤40, 40-60, and ≥60 years). We used Kaplan-Meier survival function estimates, and the log-rank test to compare incidence rates across center-and sex-specific quartiles of the 24-hour systolic blood pressure or eGFR. We applied Cox regression to compute standardized hazard ratios (HRs), which express the risk for a 1-SD increase in the independent variables. We checked the proportional hazards assumption by the Kolmogorov-type supremum test and by testing the interaction terms between follow-up duration and the risk variables. The HRs were adjusted for center, sex, age, body mass index, smoking and drinking, serum cholesterol, history of cardiovascular disease, diabetes mellitus, and treatment with antihypertensive drugs. To adjust for center, we pooled participants recruited in the framework of the European Project on Genes in Hypertension (Kraków, Novosibirsk, Padova, and Pilsen). Additionally, in fully adjusted models, when computing the HRs for the ABP 24 , we accounted for eGFR and vice versa. We tested heterogeneity in the HRs across subgroups by introducing the appropriate interaction term in the Cox model. We plotted the 10-year risk of all-cause mortality and cardiovascular events in relation to the 24-hour systolic blood pressure and eGFR. Finally, we applied the generalized R 2 statistic (see Expanded Methods in the online-only Data Supplement) 34 to assess the refinement in risk prediction by adding the 24-hour blood pressure or eGFR to Cox models on top of other covariables. Statistical significance was an α-level of <0.05 on 2-sided tests. 1%) . Among the 2962 participants, who underwent testing for proteinuria, 67 had a positive dipstick test (any degree of proteinuria) and 179 had a 24-hour urinary albumin excretion of ≥30 mg; the number of participants with severe proteinuria on dipstick testing or having a 24-hour albuminuria in excess of 300 mg amounted only to 77 and 2, respectively.
The center-and sex-specific quantiles of serum creatinine and eGFR are listed in Tables S1 and S2 (available in the online-only Data Supplement). Across center-and sex-specific quartiles of eGFR, baseline characteristics were significantly different (P≤0.05), with the exception of the percentage of participants drinking alcohol ( Table 1) .
Incidence of Events
In the overall study population, the median follow-up was 9.3 years (fifth to 95th percentile interval, 2. 
Exploratory Analyses
In exploratory analyses, we plotted death and event rates standardized for center, sex, and age across quartiles of the 24-hour systolic blood pressure and eGFR ( Figure 1 ). Rates consistently increased with higher blood pressure and lower eGFR. The P values for linear trend were significant (P≥0.039) with the exception of those for noncardiovascular mortality (P≥0.71). We obtained similar findings by plotting Kaplan-Meier survival function estimates ( Figure 2 ) for cardiovascular mortality and the composite cardiovascular end points by center-and sex-specific quartiles of the 24-hour systolic blood pressure and eGFR. P values for the corresponding log-rank tests were significant (P<0.0001).
Mortality
In multivariable Cox models, we adjusted for center, sex, age, body mass index, smoking and drinking, serum cholesterol, history of cardiovascular disease, diabetes mellitus, and antihypertensive drug treatment. In adjusted models, not including eGFR (Table 2) , the 24-hour systolic blood pressure predicted both total and cardiovascular mortality (P≤0.008), but not noncardiovascular mortality (P=0.46). In adjusted models, not including the 24-hour systolic blood pressure, eGFR predicted cardiovascular mortality (P=0.012), but not all-cause and noncardiovascular mortality (P≥0.23). In fully adjusted models, which included both 24-hour systolic blood pressure and eGFR, these findings were consistent. The R 2 statistics for adding eGFR as a predictor of cardiovascular mortality over and beyond the 24-hour systolic blood pressure was 0.13% (Table 3) , which was 2.6 times less than for adding the 24-hour systolic blood pressure. The interaction terms between 24-hour systolic blood pressure and eGFR in relation to the mortality outcomes were nonsignificant (0.082≤P≤0.89). Figure 3 shows the 10-year absolute risk of cardiovascular mortality associated with the 24-hour systolic blood pressure and eGFR in the whole study population.
Fatal and Nonfatal Cardiovascular Events
In adjusted analyses, not including eGFR, the 24-hour systolic blood pressure predicted all of the fatal combined with nonfatal outcomes (P≤0.0056). In adjusted models, not including the 24-hour systolic blood pressure, eGFR only predicted the composite cardiovascular end point and fatal plus nonfatal and cardiovascular (CV) events (C and D) across quartiles of the 24-hour systolic blood pressure (A and C) and estimated glomerular filtration rate (eGFR) (B and D). The scale on the horizontal axis is ascending for blood pressure and descending for eGFR. Incidence rates were standardized for center, sex, and age groups (<40, 40-60, and ≥60 years) by the direct method. The number of events contributing to the rates is presented. All P values for trend were significant. stroke (P≤0.035). In fully adjusted models, which included both 24-hour systolic blood pressure and eGFR, these findings were consistent. The R 2 statistics for adding eGFR as predictor of the composite cardiovascular end point or stroke on top of 24-hour systolic blood pressure were 0.09% or 0.14%, respectively. The refinement in risk prediction by eGFR was 7 to 13 times less than for the 24-hour systolic blood pressure. The interaction terms between 24-hour systolic blood pressure and eGFR in relation to the combined fatal plus nonfatal cardiovascular outcomes were nonsignificant (0.31≤P≤0.78). Figure 3 shows the 10-year absolute risk of the combined cardiovascular end point associated with the 24-hour systolic blood pressure and eGFR in the whole study population.
Sensitivity Analyses
Using 24-hour diastolic instead of 24-hour systolic blood pressure produced results similar to those in Tables 2 and 3  (see Tables S3 and S4 ). Sensitivity analyses of cardiovascular mortality (Table S5 ) and the composite cardiovascular end point (Table S6) , in which we excluded 1 center at a time, produced results similar to those in Table 2 .
Furthermore, we did sensitivity analyses for cardiovascular mortality and the composite cardiovascular end point, while stratifying for sex, presence versus absence of hypertension on conventional blood pressure measurement, eGFR <60 versus ≥60 mL/min per 1.73 m 2 , and European, Asian, or South American ethnicity. In all strata, the 24-hour systolic blood pressure remained a significant predictor of cardiovascular mortality and the composite cardiovascular end point. In models including 24-hour systolic blood pressure and all other covariables, eGFR remained a significant predictor of cardiovascular mortality in 610 patients with eGFR <60 mL/min per Table S7 . The interaction terms of proteinuria (0.1) with the 24-hour systolic blood pressure or 1/eGFR were all nonsignificant (P≥0.06).
Discussion
Our current meta-analysis of individual data included >5322 people randomly recruited from 11 populations and covered on average 9.3 years of follow-up, during which 513 people died and 555 experienced a major cardiovascular complication. The key finding was that, while accounting for the 24-hour systolic blood pressure and other covariables, eGFR was a significant 
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Figure 2. Kaplan-Meier survival function estimates for total mortality (A and B) and for all cardiovascular events (C and D) by center-and sex-specific quartiles of the 24-hour systolic blood pressure (A and C) and eGFR (B and D). All P values for the log-rank test were significant. eGFR indicates estimated glomerular filtration rate.
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and independent predictor of cardiovascular mortality, all of the cardiovascular events combined and fatal and nonfatal stroke. However, the proportion of the risk explained by eGFR is low. Several population studies confirmed that eGFR is a predictor of risk, especially at levels <60 mL/min per 1.73 m The current study extends these previous findings in various ways. First, in addition to total and cardiovascular mortality, eGFR is the glomerular filtration rate estimated from the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI), as given in reference 22. Hazard ratios, presented with 95% CI, express the risk associated with a 1-SD increase in 24-h systolic blood pressure or a 1-SD decrease in eGFR. For eGFR, the inverse of the hazard ratio is presented, so that higher values, associated with lower eGFR, reflect higher risk. All models were adjusted for center, sex, age, body mass index, smoking and drinking, serum cholesterol, diabetes mellitus, history of cardiovascular disease, and antihypertensive treatment. Adjusted models (A) include either the 24-h systolic blood pressure or eGFR, whereas fully adjusted models (FA) include both 24-h systolic blood pressure and eGFR in addition to the aforementioned covariables. eGFR indicates estimated glomerular filtration rate.
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our analyses included all fatal combined with nonfatal cardiovascular end points and fatal and nonfatal cardiac events and stroke. Lower eGFR predicted the composite cardiovascular end point and stroke. Konishi et al 36 followed 1809 Japanese patients, who underwent a complete coronary revascularization. Over 11.4 years, 127 strokes occurred. In multivariable-adjusted Cox regression, an eGFR of <60 mL/ min per 1.73 m 2 (321 patients) was associated with a 66% higher risk of stroke. 36 Second, to our knowledge, our current study is the first to consider the relative contributions of the ABP 24 and renal function as estimated from serum creatinine in risk stratification. Blood pressure was the overriding risk factor. However, our study population included <10% of participants with an eGFR of <60 mL/min per 1.73 m 2 (Table  S2 ). Previous studies demonstrated that the risk of all-cause and cardiovascular mortality exponentially increases below this threshold across the stages of renal dysfunction. Third, in contrast to other reports, we did not categorize eGFR according to proposed classification of renal dysfunction, but we analyzed eGFR as a continuous variable.
Equations to estimate the GFR based on the serum creatinine concentration are routinely used to assess renal function. The most commonly used equation is the Modification of Diet in Renal Disease (MDRD) Study equation. 37 The MDRD equation was developed in patients with kidney disease and tends to underestimate the measured GFR at levels of 60 mL/ min per 1.73 m 2 , and thus overestimate the prevalence of renal dysfunction. In the present study, we applied the newer CKD-EPI formula, 22 which now has been tested in various populations and provides a more accurate estimate of the GFR. 38 Recruitment of the population cohorts included in IDACO already started 30 years ago. To measure serum creatinine, from which eGFR is extrapolated, all centers applied Jaffe's method, 19 with modifications. 20, 21 However, it is unlikely that the serum creatinine levels are comparable across centers. Moreover, serum creatinine varies across ethnicities and is lower in women than in men. To overcome this limitation, we based part of our analyses on center-and sex-specific quartiles of eGFR. In analyses using eGFR as a continuous variable, we adjusted for center and sex. Finally, our results remained consistent, when we excluded one cohort at a time or when stratified for sex or ethnicity.
The strong points of our current report are the use of ambulatory monitoring to assess blood pressure; the relatively large sample size representing populations from Europe, Asia, and South America; and the large number of events, which occurred over a median follow-up of >10 years. Nevertheless, our study also has limitations. First, ≈4000 participants did not have a measurement of serum creatinine at baseline. Participants having a serum creatinine measurement were not specifically selected. Second, several investigators demonstrated that eGFR and albuminuria had additive value in profiling the risk of adverse outcomes in patients 39, 40 as well as populations. 2, 6 We did not systematically collect information on proteinuria in the IDACO cohorts. Nevertheless, we did a sensitivity analysis in 2962 participants, in whom information on proteinuria had been collected, albeit with different methods. The nonsignificant interaction terms suggested that in our cohorts, proteinuria did not modify the risk prediction provided by the 24-hour blood pressure or eGFR. However, the subgroup with proteinuria was small and experienced too few events to run a robust analysis. Third, our results suggest that 24-hour systolic blood pressure and eGFR act as additive risk factors for selected outcomes and that they do not potentiate eGFR; B and D) . Risk function estimates were standardized to the mean distribution in the whole study population of cohort, sex, age, body mass index, smoking and drinking, serum cholesterol, history of cardiovascular disease, diabetes mellitus, and treatment with antihypertensive drugs. The 24-hour blood pressure is represented by 4 risk functions corresponding with levels of 100, 120, 140, and 160 mm Hg and eGFR by 4 risk functions corresponding with levels of 45, 60, 90, and 110 mL/min per meter squared Plotted values of the eGFR and 24-hour systolic blood pressure span the fifth to 95th percentile interval. P values are for the independent effect of the estimated glomerular filtration rate (P eGFR ) and 24-hour blood pressure (P SBP ). n p and n e indicate the number of participants at risk and the number of events. ) in only 58 (1.1%). This might explain why blood pressure and eGFR did not behave as synergistic risk factors. Our current results can therefore also not be extrapolated to patients with reduced renal function. Fifth, the R 2 statistic is not a perfect measure of the variation explained by Cox models. R 2 values can be compared within, but not across studies because of the dependence on censoring. Nevertheless, a measure of explained variance is crucial for the correct interpretation of the prognostic value of a risk factor. P values of HRs do not suffice to compare indicators of risk. Finally, our analysis rested on 11 population-based cohorts with an overrepresentation of European subjects and might not be representative for other ethnic groups, in particular blacks, who might be more susceptible to renal dysfunction.
Perspectives
In the general population, at levels predominantly >60 mL/ min per 1.73 m 2 , eGFR is a weaker predictor of outcome than the 24-hour systolic blood pressure. This does not mean that clinicians should lose interest in measuring glomerular filtration as an index of renal dysfunction or to refine risk stratification. Serum creatinine and creatinine clearance, although most widely used, might lack sensitivity, in particular in the presence of obesity or advanced age. Cystatin C and β-trace protein might be more reliable biomarkers not only to screen for renal dysfunction but also to stratify for cardiovascular risk and to predict the long-term outcome of a variety of patients. [41] [42] [43] Finally, we are currently addressing the role of the self-measured blood pressure at home in refining risk prediction over and beyond classic risk factors. 44 We will investigate whether we can confirm our current findings, if home rather than ABP measurement is used in conjunction with eGFR. 
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What Is New?
• No previous study addressed whether in the general population eGFR predicts cardiovascular outcome over and beyond the ABP 24 . Population studies on eGFR report only on total and cardiovascular mortality, but not on fatal combined with nonfatal outcomes.
What Is Relevant?
• Fully adjusted Cox models included both ABP 24 and eGFR. ABP 24 predicted (P≤0.008) both total (513 deaths) and cardiovascular (206) mortality; eGFR only predicted cardiovascular mortality (P=0.012). Furthermore, ABP 24 predicted (P≤0.0056) fatal combined with nonfatal events as a result of all cardiovascular causes (555 events), cardiac disease (335), or stroke (218), whereas eGFR only predicted (P≤0.035) the composite cardiovascular end point and stroke. The interaction terms between ABP 24 and eGFR were nonsignificant (P≥0.082). . For eGFR, the inverse of the hazard ratio is presented, so that higher values, associated with lower eGFR, reflect higher risk. All models were adjusted for center, sex, age, body mass index, smoking and drinking, serum cholesterol, diabetes mellitus, history of cardiovascular disease, and antihypertensive treatment. Adjusted models (A) include either the 24-h diastolic blood pressure or eGFR, while fully adjusted models (FA) include both 24-h diastolic blood pressure and eGFR in addition to the aforementioned covariables.
Risk Stratification by ABP and eGFR -10- Hazard ratios, presented with 95% confidence interval (CI), express the risk associated with a 1-SD increase in 24-h systolic blood pressure (14.2 mm Hg) or a 1-SD decrease in eGFR (16.7 ml/min/1.73 m 2 ). For eGFR, the inverse of the hazard ratio is presented, so that higher values, associated with lower eGFR, reflect higher risk. All models were adjusted for center, sex, age, body mass index, smoking and drinking, serum cholesterol, diabetes mellitus, history of cardiovascular disease, and antihypertensive treatment and include both the 24-h systolic blood pressure or eGFR. EPOGH (European Project on Genes in Hypertension) includes participants recruited at Kraków, Novosibirsk, Padova and Pilsen.
Risk Stratification by ABP and eGFR -13- eGFR is the glomerular filtration rate estimated from the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI), as given in reference 17. Hazard ratios, presented with 95% confidence interval (CI), express the risk associated with a 1-SD increase in 24-h systolic blood pressure or a 1-SD decrease in eGFR. For eGFR, the inverse of the hazard ratio is presented, so that higher values, associated with lower eGFR, reflect higher risk. See Methods for the definition of proteinuria. All models were adjusted for center, sex, age, body mass index, smoking and drinking, serum cholesterol, diabetes mellitus, history of cardiovascular disease, and antihypertensive treatment and include both the 24-h systolic blood pressure or eGFR.
